ClinicalTrials.gg
RecruitingNCT06863883MASTERUpdated Jun 2, 2026

Aortic Stenosis - Prognosis, Risk and Outcomes

An observational study in Aortic Stenosis Disease, sponsored by Vastra Gotaland Region. Recruiting at 2 sites in Sweden. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Vastra Gotaland Region · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Aortic Valve Stenosis with a site in Sweden — 11 open to participants now, 17 under way, none of them phase 3. Aortic Valve Stenosis · Sweden.

Planned enrollment
10th of 19
300 · median 300
Started
2025
with 2 others
Observational
19 of 38
5 open now
Primary completion
2030-12
later than 16 of 16 live
Registered
35th of 38
by date
Lead sponsor
2 of 38
Vastra Gotaland Region

Among the 38 studies in Aortic Valve Stenosis with a site in Sweden, this one is the 10th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2025, is one of 19 observational ones, reaches primary completion later than 16 of the 16 other live ones, and was the 35th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

11 of the 38 studies in Aortic Valve Stenosis with a site in Sweden are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Aortic Valve Stenosis with a site in Sweden, or all of them as a file.
02

Study summary

The investigators will prospectively enroll 300 patients undergoing TAVI at Sahlgrenska University Hospital, which is the second largest TAVI hospital in Sweden. Eligible patients should have a clinical indication for aortic valve replacement with TAVI and have preprocedural clinical investigations with echocardiography (UCG) and CCT and provide written informed consent. UCG, electrocardiogram (ECG) and blood samples will be taken in addition to clinical status, NYHA-class and collection of outcome events the day before the procedure, 1±2 hours, 24 ±6hours and daily after the procedure until discharged from Sahlgrenska. Further follow-up will be scheduled day 14, 30, 180, 365 and yearly. Cardiac MRI will be performed before, at 14 days and at 180 days after TAVI. Brain MRI will be performed before and 24± hours after TAVI. Cardiac CT will be performed at 180 days after TAVI.

Read the detailed description
  • Study procedures UCG, cardiac CT and ECG before the TAVI procedure are done as standard of care. Study-related imaging procedures are non-invasive methods that carry no risk of serious adverse events for the study subject.
  • Ultrasound cardiogram (UCG) UCG is a non-invasive imaging procedure that uses ultrasound to image the heart in real- time. UCG carries no risk of causing serious adverse events for the study participants.
  • Quality of life Quality of life will be assessed using EQ-5D-5L at baseline and at 14 days, 30 days, 180 days and yearly after the procedure.
  • ECG ECG has been the cornerstone of cardiovascular medicine for decades and is part of routine clinical practice for all patients undergoing TAVI at cardiology departments across the world. It is a non-invasive test that carries no risk of serious adverse events.
  • MRI Cardiac Magnetic Resonance imaging (CMR) will be used to assess the degree of cardiac remodeling and hemodynamic and blood flow parameters, e.g. turbulence, as a sub-study within in the larger study. Brain Magnetic Resonance imaging (brain MRI) will be used to assess micro-embolism and ischemic stroke related to the TAVI procedure.

CMR and Brain MRI poses no increased risk of causing serious adverse events for patients participating in the study. However, patients with clear contraindication will not be included to the study. (e.g. patients with MRI non-compatible metal device present in body, claustrophobia or for other reasons set at the local clinic). Patients with kidney failure (estimated glomerular filtration rate \<30 ml/kg/min,) will not be given MRI contrast medium.

MRI is planned before the TAVI procedure (baseline), 24 hours (Brain MRI) and at 180 days (CMR) after TAVI.

  • Cardiac CT Cardiac CT before TAVI is part of routine clinical care and used for procedural planning. An additional cardiac CT will be performed as a sub-study at 180 days after the TAVI procedure. The procedure will be used to assess the placement of the TAVI-valve in the native aortic annulus, e.g. the depth of the valve, the alignment of the commissures of the prothesis in relation the native commissures and the coronary ostia and be used to simulate the possibilities to perform a redo-TAVI if the need should arise. Patients with kidney failure (estimated glomerular filtration rate \<30 ml/kg/min,) will not be given CT contrast medium.
  • Storing of blood samples for future analysis Plan to save blood samples (for subjects that have consented to this part) for the purpose of future analysis for metabolomics, proteomics and circulating miRNA. The amount of blood for biobank storage will be 21 ml collected at four time points per study participant, i.e. max 84 ml per patients.
03

Conditions studied

  • Aortic Stenosis Disease

Keywords

  • TAVI
  • Cardiac remodelling
  • Aortic stenosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

We will prospectively enroll 300 patients undergoing TAVI at Sahlgrenska University Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with clinical indication for aortic valve replacement and scheduled for TAVI
  • Patient willing and able to provide signed

Exclusion criteria

Exclusion Criteria:

  • Inability to provide Additional exclusion criteria for MRI
  • Estimated \<30 ml/kg/min (MRI without contrast can be performed )
  • Claustrophobia or inability to tolerate confined spaces.
  • Non-compatible metal device present in body
  • Any other for MRI as per local guidelines Additional exclusion criteria for the CT substudy
  • Estimated glomerular filtration rate \<30 ml/kg/min (CT without contrast can be performed)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • TAVI patients

    300 patients undergoing TAVI at Sahlgrenska University Hospital

06

What researchers measure

Primary outcomes

  1. Cardiac damage

    To study change in stage of cardiac damage (stage 0-4) by echocardiography.

    Time frame: Baseline and 180 days

Secondary outcomes

  1. Change in echocardiography parameters

    To study E/é ratio in echocardiography derived parameters indicating cardiac damage (delta%)

    Time frame: Baseline and at 14, 30 and 180 days

  2. Change in echocardiography parameters

    To study Left ventricular mass change on echocardiography (delta gram)

    Time frame: Baseline and at 14, 30 and 180 days

  3. Left Atrial -strain

    To study change in LA-strain derived by echocardiography (delta %)

    Time frame: Baseline and at 14, 30 and 180 days

  4. Change in echocardiography parameters

    To study the influence of effectiv orfice area (cm2)of the aortic valve on cardiac damage (stage 0-4)

    Time frame: Baseline and at 14, 30 and 180 days

  5. Cardiac Magnetic Resonance (CMR)

    Change in CMR derived parameters Left ventricular mass (delta gram)

    Time frame: Baseline and at 14 and 180 days

07

Study locations

2 of 2 sites recruiting
  • Departement of Cardiology,
    Gothenburg, 413 45, Sweden
    Recruiting
  • Departement of Cardiology
    Gothenburg, 413 45, Sweden
    Recruiting
    • Oskar Anerås, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2030, 69 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 69 months is above that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Mar 7, 2025
StartActual
Mar 4, 2025
Primary completionEst.
Dec 2030
CompletionEst.
Jun 2031
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06863883
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Mar 4, 2025
Primary completion
Dec 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
Jun 2, 2026

Study contacts

Oskar Angerås, MD, PhD
Contact
oskar.angeras@vgregion.se
+46 313421000
Björn Redfors, MD, PhD, Professor
Contact
bjoern.redfors@wlab.gu.se
031342100

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion